Videos
Smartwatch for Diabetics Under Development
Smartwatch for Diabetics Under Development
K'Watch Glucose can measure and display glucose levels continuously and discreetly for patients with diabetes.
By Michael Barbella, Managing Editor09.01.22
French startup PKvitality is developing K'Watch Glucose, the first Continuous Glucose Monitor (CGM) in the form of a smartwatch, designed specifically for diabetic patients.
PKvitality is touting the K'Watch as the world's first CGM device for tracking glucose levels discreetly and continuously at the wrist. This system, currently at the stage of clinical studies, measures the level of glucose in the interstitial fluid through micro-tips. It will thus offer a painless and non-stigmatizing experience to the user.
Results of a third clinical study suggest a promising future for the development of K’Watch. Indeed, the measurement of glucose levels for patients with type 1 and type 2 diabetes is commonly a demanding process whether in terms of accuracy, tolerance, or pain. Based on these criteria, the objective has been more than achieved since K’Watch obtains a 16% margin of error on the accuracy (MARD) for continuous glucose measurement against the 17%-18% initially desired. This efficiency is the result of in-depth improvements in the patch and the algorithm.
In the past few months, PKvitality has also unveiled the results of its previous two clinical studies, which showed a 19% MARD in continuous glucose analysis. In addition, the studies revealed an excellent user experience with very good tolerance for patients with no adverse effects, pain, or irritation during use. The trials took place at the AMCR Institute, a clinical research center focused on diabetes and obesity with worldwide renowned expertise in medical devices related to metabolism.
"With K'Watch, we seek to offer people with diabetes a technological innovation that will accompany them in their daily lives," said Luc Pierart, founder of PKvitality. "Although we started clinical trials at the end of 2021, we are making rapid and very conclusive progress. This acceleration towards the precision required in our clinical trials makes us confident in the development of our product. We are a few months away from validating our project and offering a CGM that meets the expectations of diabetes patients: painless, without adhesive issues, discreet and ultra-practical.”
PKvitality is a health & sport bio-wearable startup currently working on the K’Watch Glucose, a CGM device in the form of a smartwatch and the K’Watch Athlete, a smartwatch for providing real-time monitoring of lactic acid—an indicator of muscle fatigue—to significantly improve training and performance among athletes.
PKvitality is touting the K'Watch as the world's first CGM device for tracking glucose levels discreetly and continuously at the wrist. This system, currently at the stage of clinical studies, measures the level of glucose in the interstitial fluid through micro-tips. It will thus offer a painless and non-stigmatizing experience to the user.
Results of a third clinical study suggest a promising future for the development of K’Watch. Indeed, the measurement of glucose levels for patients with type 1 and type 2 diabetes is commonly a demanding process whether in terms of accuracy, tolerance, or pain. Based on these criteria, the objective has been more than achieved since K’Watch obtains a 16% margin of error on the accuracy (MARD) for continuous glucose measurement against the 17%-18% initially desired. This efficiency is the result of in-depth improvements in the patch and the algorithm.
In the past few months, PKvitality has also unveiled the results of its previous two clinical studies, which showed a 19% MARD in continuous glucose analysis. In addition, the studies revealed an excellent user experience with very good tolerance for patients with no adverse effects, pain, or irritation during use. The trials took place at the AMCR Institute, a clinical research center focused on diabetes and obesity with worldwide renowned expertise in medical devices related to metabolism.
"With K'Watch, we seek to offer people with diabetes a technological innovation that will accompany them in their daily lives," said Luc Pierart, founder of PKvitality. "Although we started clinical trials at the end of 2021, we are making rapid and very conclusive progress. This acceleration towards the precision required in our clinical trials makes us confident in the development of our product. We are a few months away from validating our project and offering a CGM that meets the expectations of diabetes patients: painless, without adhesive issues, discreet and ultra-practical.”
PKvitality is a health & sport bio-wearable startup currently working on the K’Watch Glucose, a CGM device in the form of a smartwatch and the K’Watch Athlete, a smartwatch for providing real-time monitoring of lactic acid—an indicator of muscle fatigue—to significantly improve training and performance among athletes.
